Review Article

Current Strategies to Generate Human Mesenchymal Stem Cells In Vitro

Jennifer Steens and Diana Klein

Institute for Cell Biology (Cancer Research), University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Correspondence should be addressed to Diana Klein; diana.klein@uk-essen.de

Received 26 April 2018; Revised 31 July 2018; Accepted 9 August 2018; Published 26 August 2018

Academic Editor: Stan Gronthos

Copyright © 2018 Jennifer Steens and Diana Klein. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mesenchymal stem cells (MSCs) are heterogeneous multipotent stem cells that are involved in the development of mesenchyme-derived evolving structures and organs during ontogeny. In the adult organism, reservoirs of MSCs can be found in almost all tissues where MSCs contribute to the maintenance of organ integrity. The use of these different MSCs for cell-based therapies has been extensively studied over the past years, which highlights the use of MSCs as a promising option for the treatment of various diseases including autoimmune and cardiovascular disorders. However, the proportion of MSCs contained in primary isolates of adult tissue biopsies is rather low and, thus, vigorous ex vivo expansion is needed especially for therapies that may require extensive and repetitive cell substitution. Therefore, more easily and accessible sources of MSCs are needed. This review summarizes the current knowledge of the different strategies to generate human MSCs in vitro as an alternative method for their applications in regenerative therapy.

1. Introduction

Among the adult stem cells, MSCs are supposed to be the most promising stem cell type for cell-based therapies [1–4]. Compared with less differentiated pluripotent stem cells, in particular embryonic stem cells or induced pluripotent stem cells (iPSCs), MSCs are well tolerated and lack ethical concerns as well as teratoma-formation and histocompatibility issues [5–7] [8, 9]. Adult MSCs are multipotent cells, which are commonly characterized by their ability to adhere on plastic, by the expression of a typical panel of MSC surface markers (CD105(+), CD73(+), CD90(+), CD11b(−), CD79a(−), CD19(−), and human leukocyte antigen (HLA-DR) (−)), and the ability to differentiate into mesenchymal and nonmesenchymal tissues in vitro and in vivo [10, 11].

Once therapeutically applied, MSC can either act directly by homing to particular anatomical sites after transplantation and differentiating into specific cell types to locally restore the damaged tissue. Even more important, MSCs can support tissue regeneration by a paracrine (“hit and run”) mechanism of action, such as secretion of multiple bioactive molecules capable of stimulating recovery of injured cells and inhibiting inflammation [12–14]. In addition, MSCs lack immunogenicity and possess the ability to perform immunomodulatory functions [15, 16]. These unique properties have promoted numerous applications of MSCs which currently undergo hundreds of clinical trials (http://www.clinicaltrials.gov) for disease treatments including graft versus host disease, chronic obstructive pulmonary disease, Crohn’s disease, or even multiple sclerosis [17–20]. Genetically modified MSCs were further used to enable targeted delivery of a variety of therapeutic agents in malignant diseases [21–23].

The classical known reservoir of MSCs is the bone marrow, but nowadays, MSCs are effectively isolated from almost every organ such as adipose tissue, cartilage, muscle, liver, blood, and blood vessels [4, 24–29]. However, there are several limitations for the vigorous in vitro expansion of ex vivo isolated adult MSCs: a decline of their plasticity and in vivo potency over time was reported, as well as accumulated DNA abnormalities and replicative senescence [30–35]. In addition, variations of the quality of obtained donor cells and tissue sources have caused numerous inconsistencies in
the reported in vivo effectiveness of MSCs [36–39]. Therefore, more reliable sources of MSCs remain an important problem.

To circumvent many of these issues, alternative methods to generate therapeutically sufficient numbers of MSCs in vitro were established. MSCs for autologous cell replacement therapy can be derived from immune-compatible somatic cells, which possesses huge clinical potential. However, the large-scale production of human MSCs for regenerative cell therapies depends on well-defined, highly reproducible culture and differentiation conditions. This review will focus on the different methods to generate therapeutically active MSCs in vitro.

2. Patient-Specific MSCs

MSCs can be derived from different donor cells via 2 primary strategies: (1) direct conversion or induced transdifferentiation of patient-specific somatic cells or (2) differentiation from reprogrammed (pluripotent) somatic cells (iPSCs) (Figure 1). No matter which way of in vitro generation is chosen, MSCs emerge then from the proliferating donor cells in the presence of mesodermal growth factors, growth factor inhibitors, and small molecules. When iPSCs were used, MSCs can even be derived spontaneously by depriving the pluripotent signals from the culture conditions. As an alternative pathway, patient-specific somatic cells can directly programmed/transdifferentiated to MSCs which would avoid the need for prior reprogramming those cells back the pluripotent stage. Hypothetically, human MSCs could also be obtained by a direct programming approach, by ectopic expression of MSC-specific transcription factors in iPSCs and somatic cells, or by the introduction of cell type-specific microRNA molecules that functions in RNA silencing and posttranscriptional regulation of MSC gene expression. Morphology-based manual selection and/or sorting for cell type-specific cell surface markers using flow cytometry or immunomagnetic separation might further be used to increase purity of generated MSCs. The generation of patient- and disease-specific iPSCs is a valuable tool for regenerative therapies, for example, restoration of function through transplantation of ex vivo manufactured cells.

Figure 1: Patient-specific adult MSCs. Somatic cells (e.g., fibroblasts and peripheral blood cells) can be isolated from individual healthy or diseased donors (biopsy) and (i) directly converted into MSCs or (ii) reprogrammed into iPSCs by the introduction of the common transcription (Yamanaka) factors OCT4, SOX2, KLF4, and c-MYC. iPSCs were characterized by indefinite self-renewal and pluripotent differentiation capacities and, thus, represent an attractive source to generate unlimited cell numbers for targeted differentiation into MSCs. For regenerative therapy, only donor cells that have reached a particular differentiation stage could be used, which means that the iPSCs must first be brought to an ordered differentiation path. MSC differentiation of iPSCs is initiated either spontaneously (by deprivation of pluripotent signals) or specifically directed by the induction of mesodermal differentiation, followed by treatment with MSC-specific growth factors that allows then the isolation and expansion of the selected MSCs under chemically defined cell culture conditions. As an alternative pathway, patient-specific somatic cells can directly programmed/transdifferentiated to MSCs which would avoid the need for prior reprogramming those cells back the pluripotent stage. Hypothetically, human MSCs could also be obtained by a direct programming approach, by ectopic expression of MSC-specific transcription factors in iPSCs and somatic cells, or by the introduction of cell type-specific microRNA molecules that functions in RNA silencing and posttranscriptional regulation of MSC gene expression. Morphology-based manual selection and/or sorting for cell type-specific cell surface markers using flow cytometry or immunomagnetic separation might further be used to increase purity of generated MSCs. The generation of patient- and disease-specific iPSCs is a valuable tool for regenerative therapies, for example, restoration of function through transplantation of ex vivo manufactured cells.
3. Human Embryonic Stem Cell-Derived MSCs

The first reports on MSCs generated from pluripotent stem cells were performed with pluripotent embryonic stem cells before iPSCs came into focus. Xu et al. isolated human embryonic fibroblast-like cells (HEF1 cells) from pluripotent human embryonic H1 stem cells after induction of differentiation by small aggregate formation (embryonic bodies) and subsequent cultivation in HEF1 medium (knockout- (KO-) DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS) and nonessential amino acids) [43]. The remaining fibroblast-like cells were further infected with a retrovirus expressing human telomerase reverse transcriptase (hTERT) which extended their replicative capacity, resulting in immortal human HEF1-hTERT cells. These cells exhibited a similar marker profile like MSCs and had the capacity to differentiate into cells of the osteogenic lineage, as telomerase expression in human MSCs had already been shown to enhance an osteogenic differentiation potential [44].

Only one year later, a more directed approach for the in vitro generation of MSCs was reported. Barberi et al. used the same embryonic H1 stem cell line (together with H9 embryonic stem cells) and cocultured these cells with the mesoderm embryonic cell line OP9 (mouse bone marrow stromal cells) to induce mesodermal differentiation in the presence of 20% heat-inactivated FBS (in alpha-MEM) for approximately 40 days prior flow-activated cell sorting (FACS) for the MSC marker CD73 [45]. This simple and quite unspecific differentiation protocol yielded multipotent mesenchymal precursors from human embryonic stem cells with typical average of 5% CD73-positive cells (in the mixed culture of OP9 and differentiated embryonic stem cells), which expressed several classical MSC markers and differentiation capabilities [45]. Gene expression profiling in addition confirmed a MSC-specific expression profile of differentiated MSC as compared to primary human bone marrow-derived MSCs including the MSC protein DSC54, neuropilin, hepatocyte growth factor, forkhead box D1, and notch homolog [45]. Thus, the basis for the in vitro generation of MSC differentiated from pluripotent stem cells which followed the classical MSC characteristics was made.

A number of reports followed to derive MSCs from human embryonic stem cells. A more specific approach was provided by Lian et al. who established a protocol for the derivation of clinically compliant MSCs, which were derived from Hues9 and H1 human embryonic stem cells without the use of animal products [46]. Mesodermal differentiation was induced by plating trypsinized embryonic stem cells in MSC growth medium supplemented with serum replacement medium, basic fibroblast growth factor (bFGF/FGF2), and platelet-derived growth factor AB (PDGF-AB) on gelatinized tissue culture plates. After one week of culture, CD105(+) and CD24(−) differentiated cells that comprised approximately 5% of the culture were sorted via FACS. Classical MSC characteristics were proven including gene expression analysis as compared to bone marrow MSCs [46]. In addition, the CD24-negative isolation allowed for the selection of the desired cells deprived from remaining non- or partially differentiated embryonic stem cells, as CD24 was identified as a human embryonic stem cell marker. Although the authors successfully reduced the unacceptable risks of tumorigenicity or potential xenozootic infection by circumventing the coculture with murine cells, the authors did not completely circumvent the use of animal products, namely, gelatin for coating and antibodies for flow cytometry purification.

This issue was addressed in the following study. Karlsson et al. established an optimized protocol resulting in the simple and reproducible derivation of mesenchymal progenitors from xeno-free, undifferentiated human embryonic stem cell lines [47, 48]. Therefore, undifferentiated embryonic stem cells were removed from the supporting feeder layer, enzymatically dissociated, and plated as high-density cultures on plastic dishes coated with human recombinant gelatin in medium supplemented with human serum (10%) and human recombinant bFGF. After 7 days, the resulting outgrowth of heterogeneous cell types was further passaged and cultured until a homogeneous culture with mesenchymal progenitor morphology (at passage 2-3) was achieved [48, 49]. Resulting MSC characteristics as well as microarray analysis confirmed the MSC nature of generated MSCs as compared to MSCs isolated from human bone marrow aspirates from the iliac crest [49]. Preclinical evaluation of implanted human embryonic stem cell-derived mesenchymal progenitor cells further revealed that generated cells gave rise to homogeneous, well-differentiated tissues that were exclusively of mesenchymal origin while no teratoma formation was observed [48]. The authors successfully established here a robust protocol that does not require cell transfection, coculture, cell sorting, or subjective manual selection for the xeno-free derivation of mesenchymal progenitors from diverse human embryonic stem cell lines that were safe for the use in tissue engineering and cell therapies.

Conclusively, MSCs can either be derived from human embryonic stem cells spontaneously, upon less stringent culture conditions, and in particular upon culturing in medium which is deprived of pluripotent signals, or by a specific stimulus (e.g., growth factors or inhibitors) which directs MSC differentiation. Most of these protocols were consistent and cost-effective, but inefficient, as the MSC population yielded by the unspecific differentiation methods yielded only approximately 5% MSCs. Pure cultures could then be established upon prolonged culturing, by fluorescence-activated cell sorting or by manual selection of cell populations.

4. iPSC-Derived MSCs

Human iPSCs constitute a well-characterized, generally unlimited cell source for the mass generation of lineage- and patient-specific MSCs without any ethical concerns because of their theoretical unlimited growth and differentiation potential. Human iPSC-derived MSCs were already shown to display similar features with mature MSCs at the genetic and functional levels [37, 50–52]. As already stated, the major challenge is here to establish reliable, efficient,
and scalable protocols to differentiate functionally mature adult MSCs.

The classical method for differentiating iPSCs towards MSCs is the use of media that contains a high serum concentration or MSC-typical growth factors such as bFGF after mesoderm induction [32, 50, 53–55]. Induction of mesodermal differentiation is usually achieved by embryoid body formation or mesodermal-inductive factor treatments (bone morphogenetic protein 4, activin A/nodal, bFGF, and glycogen synthase kinase 3 inhibitors or WNT ligands) in chemically defined monolayer systems. Successive treatment with MSC-specific growth factors and/or sorting for MSC-specific cell surface markers using flow cytometry or immunomagnetic separation allows then the isolation and expansion of the selected MSCs under chemically defined cell culture conditions.

A clinically compliant protocol for the MSC differentiation of human iPSCs was established by Lian et al. [56]. According to their previously established protocol for the derivation of MSCs from human embryonic stem cells, the authors used three iPSC lines (iPSC(IMR90)-5 and iPSC(IMR90)-4 cells derived from IMR90 fibroblasts as well as iPSC(foreskin)Clone1 cells derived from foreskin fibroblasts), which were cultured on gelatin-coated plastic dishes in KO-DMEM supplemented with 10% serum replacement medium in the presence of bFGF, PDGF-AB, and epidermal growth factor to foster the MSC outgrowth [46, 56]. After 1 week of culturing, CD24(−) and CD105(+) cells were isolated via FACS and clonally expanded. By this, the authors successfully generated spontaneously active MSCs which exhibited the classical MSC characteristics and furthermore the ability for self-renewal in culture for >120 population doublings without obvious loss of plasticity or onset of replicative senescence [56]. The transplanted iPSC-derived MSCs were shown to be superior in attenuation of severe hindlimb ischemia (significantly improved vascular and muscle regeneration) than adult bone marrow MSCs which may result from a better in vivo survival and to their trophic factors that protect endangered cells after ischemic injury [56]. Giuliani et al. confirmed the beneficial role of iPSC-derived MSCs as compared to bone marrow MSCs concerning survival and longevity [57]. The authors used MSC differentiated from 5 iPSC lines (H9-iPS, SA-01-iPS, PB03, PB10, and PB11) using DMEM/F12 medium supplemented with 10% heat-inactivated FBS, bFGF, and nonessential amino acids as differentiation medium. Respective iPSC-derived MSCs displayed remarkable inhibition of natural killer (NK) cell proliferation and cytolytic function, while being more resistant than adult bone marrow MSCs to preactivated NK cells, which highlights their potential to prevent allograft rejection [57]. In line with these findings, a differential expression of ion channels in iPSC-derived MSCs was shown to contribute to their higher proliferation capacity compared with classically bone marrow MSCs [58]. Among the different ion channels, increased expression of the functional KCNH1-encoded human ether-a-go-go 1 (hEAG1) potassium channel was identified being responsible for higher cell proliferative rate in iPSC-derived MSCs using the Lian protocol [56, 58].

A new method to rapidly derive MSC-like cells from human iPSCs in one step using thin, fibrillar, type I collagen as matrix that mimics the structure of physiological collagen was reported for the effective differentiation of MSC from the human dermal fibroblast-derived HDFa-YK26 iPSCs [32]. Resilient colonies of homogenous spindle-shaped cells were obtained after 10 days of culturing iPSCs in alpha-MEM supplemented with 10% FBS, magnesium L-ascorbic acid phosphate, and dexamethasone that displayed the classical MSC characteristics [32]. After 2 passages, 82.9% of the cells were CD90-positive, indicating an efficient MSC generation. Prolonged passaging on collagen type I further increased this number to 96.9% of generated MSCs. The advantage for using collagen type I or in general appropriate biomatrices matrices here offers additional means to influence cell fate through physicochemical stimulation, as collagen type I was already known to activate an epithelial-to-mesenchymal transition (EMT) of epithelial cells [32, 59]. Another single-step method to direct mesengenic differentiation of human iPSCs was reported by Chen et al., who used a small molecule inhibitor, the transforming growth factor-β pathway inhibitor SB431542 [60]. iPSCs (MR90CL2 and ES4CL1) were cultured in the presence of this inhibitor for 10 days resulting in MSCs which exhibit typical MSC characteristics that conform to the criteria of the International Society for Cell Therapy (ISCT) for classification of MSCs. Mechanistically, this study revealed that SB431542 treatment triggered both intrinsic and autocrine mechanisms in iPSCs that collectively prime a subset of cells for a mesenchymal stromal cell fate by inducing EMT [60]. This modification in terms of fostering EMT in iPSC cultures resulted in higher MSC numbers of approximately 75–96% [60]. A simplified and reproducible method for inducing iPSC into MSC-like cells that further resulted in increased percentages of generated MSCs was then presented by Hynes et al. [61]. Herein, MSC-like cells were developed from iPSC lines arising from three different somatic tissues (gingiva, periodontal ligament, and lung) by a continuous culturing of respective cells in MSC culture media (alpha-MEM supplemented with 10% FCS, sodium pyruvate, l-ascorbate-2-phosphate, nonessential amino acids, and HEPES). After 2 weeks, the resulting heterogeneous cell types were passaged as a single-cell suspension and clones of arising cells were selected based on their typical morphology. Selected clones expressed key MSC-associated markers (CD73, CD90, CD105, CD146, and CD166) and lacked expression of pluripotent markers (TRA160, TRA181, and alkaline phosphatase) and hematopoietic markers (CD14, CD34, and CD45). In vitro, iPSC-MSC-like cells displayed the capacity to differentiate into osteoblasts, adipocytes, and chondrocytes [61]. By this method, the authors reported the generation of 95% pure MSC cultures.

Most of the protocols used fetal bovine serum as supplement which provides multiple growth factors with nonspecific signals to the cultures. In contrast, providing a chemically defined medium with known morphogens that fosters the MSC differentiation is supposed to increase the yield and homogeneity of the derived MSCs. In addition to the more specific and defined medium supplements, the use
of xeno-free supplements (e.g., no animal products and no coculturing with mouse cells) would allow the generation of highly identical and clinically compliant MSC cultures from human iPSCs. Luzzani et al. used H9 human embryonic stem cells and iPSCs reprogrammed from human foreskin fibroblasts in combination with platelet lysate as a media supplement to produce pluripotent-derived MSCs (PD-MSC) within 3 to 4 weeks in a robust and consistent way [62]. The authors designed a two-stage protocol for the MSC differentiation from pluripotent stem cells. In the first step, mesodermal differentiation was induced by dissociating the pluripotent stem cell clusters and plating single-cell isolates on a reduced growth factor basement membrane matrix (Matrigel or Geltrex, a soluble and LDEV-free form of basement membrane extracted from murine Engelbreth-Holm-Swarm tumors) for 14 days in the presence of platelet lysate and supplement B27 [63]. After these 14 days, when the cells were transitioned to a mesenchymal state, the prolonged culturing was performed with plastic dishes in alpha MEM supplemented with platelet lysate (10%) for additional 7–14 days [62]. The resulting PD-MSCs were generated more efficiently as compared to cells differentiated in the presence of FBS as supplement (25 cells per pluripotent stem cells when platelet lysate was used versus 10 cells per pluripotent stem cells when FBS was used) and displayed all the MSC characteristics. Conclusively, the presented protocol used simple steps using therapy-grade platelet lysate as supplement and thus yielded significant amounts of MSCs in approximately 1 month [62]. Human serum in general as well as the derived platelet lysate (and thrombin-activated platelet releasate in plasma) turned out to be promising alternatives to FBS as a medium supplement for growing MSCs [64–66]. Although the concentrations of cytokines and growth factors in the respective supplements released by the platelets after lysing vary enormously, PDGF-AB/BB, TGF-β1, and bFGF turned out to be the essential factors (beside HGF and IGF-1) for the strong positive effect on the proliferation of MSCs [67, 68]. A potential but due to the strict protocols for blood testing minimal risk remains that the human material may contain virus or parasites [69].

In summary, robust protocols have been established to obtain patient-specific, therapeutically active MSCs from iPSCs in large amounts which will potentially open avenues towards novel, MSC-based therapies. Another straightforward strategy would be the ectopic overexpression of MSC-related genes or transcription factors in human iPSCs to generate MSCs. The in vitro generation of vascular wall-typical MSCs from iPSCs, based on a vascular wall MSC-specific gene code, was reported by our group [55, 70]. Herein, a lentiviral vector expressing a small set of recently identified human vascular wall MSC-specific HOX genes was used to directly program iPSCs into MSCs which displayed classical MSC characteristics, both in vitro and in vivo [55]. However, this forward programming approach remains limited to murine iPSCs, but it is very likely that our results will also hold true for human iPSCs as the activity of homeotic selector proteins is highly conserved throughout evolution.

5. Direct Conversion of MSCs from Somatic Cells

The main limitation for a possible therapeutic use of pluripotent stem cells and/or their derived MSCs is the medical risk to generate teratomas. Although already robust selection markers and refined experimental protocols have been established to guide human iPSCs reproducibly to MSCs, an additional negative selection against remaining pluripotent cells could be an additional option, to limit the risk of teratoma formation and foster clinical safety. As an alternative, somatic donor cells that have reached a particular differentiation stage could be used.

Meng et al. used CD34-positive cord blood and adult peripheral blood cells in combination with a single factor, namely, OCT4 to demonstrate a direct programming of patient-specific somatic cells into MSCs [71]. An episcopal or lentiviral vector-mediated OCT4 expression followed by a subsequent culture of treated cells on fibronectin in commercially available MSC Medium Kit allowed the rapid and efficient programming of human CD34(+) cells directly into MSCs. The generated MSCs were multipotent, being able to differentiate into different types of MSC progenies both in vitro and in vivo, and were not tumorigenic [71, 72]. Conformingly, Lai et al. established an effective protocol to directly convert primary human dermal fibroblasts into multipotent, induced MSC-like cells (iMSCs) [73]. A cocktail containing six chemical inhibitors (SP600125 (JNK inhibitor), SB202190 (p38 inhibitor), Go6983 (protein kinase C inhibitor), Y-27632 (ROCK inhibitor), PD0325901 (ERK1/2 inhibitor), and CHIR99021 (GSK3β inhibitor)) with or without the addition of three growth factors (TGF-β1, bFGF, and leukemia inhibitory factor (LIF)) efficiently generated functional iMSCs from human primary dermal fibroblasts (primary neonatal foreskin fibroblasts (CRIL2097) within 6 days (average rate of 38%). The generated MSCs shared similar molecular signatures with bone marrow MSCs and fulfilled all of the MSC criteria defined by ISCT, including plastic adherence, marker expressions, and multipotency differentiation. In vivo, a markedly attenuation of endotoxin-induced acute lung injury, which was paralleled by a decrease of the amounts of proinflammatory cytokines, was reported [73]. Thus, an efficient conversion method that does not involve any processes that may lead to insertional mutagenesis, resulting in MSCs with lower safety concerns for disease treatments was reported [73].

Conclusively, chemical-induced conversion or direct programming of somatic cells into MSCs is possible and augurs strong clinical potential for respective MSCs but the protocols up to now are limited.

6. The Pros and Cons

Global gene and miRNA profiling of human iPSC- and embryonic stem cell-derived MSCs demonstrated a high degree of similarity between the derived MSCs, in particular as compared to bone marrow MSCs [45, 46, 49]. Bone marrow MSCs generally serve as the gold standard against which other MSC sources are compared [74]. However, there
is a convincing evidence that MSCs from diverse tissue are different and display distinct differentiation tendencies, paracrine potential, and immune properties, but the benefit and mechanisms of these MSCs from various sources remain unexplored [75]. The significant heterogeneity in the differentiating potential of MSCs from different sources however may influence their clinical application [74, 76]. Adipose tissue-derived MSCs, for example were, shown to have a stronger inhibitory effect in the suppression of peripheral blood B, T, and NK cells than bone marrow and umbilical cord matrix-derived MSCs [77]. As another example, MSCs isolated from the placenta and adipose tissue were morphologically and immune phenotypically similar to MSCs obtained from the bone marrow, but MSCs derived from the placenta were proven to be a more optimal cellular source for the treatment of ischemic diseases [75]. A proteomic profiling of the three MSC types revealed that the highly upregulated proteins in placenta-derived MSCs, which were related to oxidative stress, peroxiredoxin activity, and apoptosis function, corresponded to the in vivo functional performance [75]. Previous reports have already demonstrated that bone marrow-derived MSCs were less effective after a therapeutically application as compared to other stem cell sources [77–82].

According to the general guidelines, MSCs from distinct tissue origins have a large number of similarities concerning their characteristics, but the isolated MSCs remain a heterogeneous cell population until a clonal expansion. Up to now, it is not clear, whether tissue-resident MSCs are the progenies of one ancestor cell lineage or the results of parallel cell developmental events [83, 84]. The tissue-specific properties of MSCs were related to the expression profiles of HOX genes that are master regulators of regional specification and organ development [46]. These HOX expression profiles can be used to distinguish functionally distinct populations of MSCs, as shown for bone marrow, umbilical cord blood, and blood vessel-derived MSCs [55, 70, 85]. However, the precise mechanisms that regulate lineage specification of the isolated heterogeneous MSCs have been largely unexplored [86, 87]. The transcriptome analyses of human MSCs revealed that expressed transcripts encode for a diverse repertoire of proteins that regulate angiogenesis, hematopoiesis, cell motility, neural activities, and immunity which finally lead to the conclusion that single cells were unlikely to possess all properties. [87–89]. The different functional attributes were relegated then to distinct subpopulations. Therefore, more effort is needed to develop clinical manufacturing protocols that reproducibly generate functionally equivalent MSC populations.

The tissue-specific homing and the activities of isolated and cultured MSCs prior to transfusion are supposed to be based on an underlying transcriptional code caused by epigenetic memory allowing them to home back to the tissue they originally were derived from [53]. In line with these findings, it was shown that vascular wall-derived MSCs were more potent than bone marrow-derived MSCs to protect lung blood vessels from the adverse late effects of radiotherapy, which supports the assumption that tissue-specific stem cells support mainly the tissue type from which they originate because of their tissue-specific action [90, 91]. Therefore, a central advantage would be the use of tissue-specific MSCs for the protection and curative treatment of the same and/or similar affected tissue that in turn would require protocols for the derivation of tissue-specific MSCs. The generation of tissue-specific MSCs from somatic cells and/or iPSCs reprogrammed from somatic cells could be achieved by transient, ectopic expression of cell type-specific transcription factors, miRNAs, or by using of epigenetic modifiers, as shown for other cell types, such as neurons or hepatocyte-like cells [92–95].

The age of MSCs may also have a major impact on their therapeutic outcome, as the differentiation potential of MSCs decreases with age [96]. Aged MSCs showed decreased proliferation rates, higher oxidative damage, and cell senescence [97]. This would argue against the derivation of MSCs from adult somatic cell types, but MSC derived from pluripotent stem cells may overcome the fact that adult MSCs have limited proliferation and differentiation capabilities. It was already suggested that every pluripotent cell may become a MSC “by default,” an event that occurs spontaneously when pluripotent stem cells are cultured under less stringent pluripotent conditions [62, 69]. However, the respective percentages of MSCs generated by these culture conditions were lower (approximately 5%) as compared to more specific culture conditions with mesoderm-specific growth factors. Epigenetic instabilities or phenotypic switches after prolonged culture might also occur because the identity of derived MSCs may not be well inherited in human iPSCs and embryonic stem cell-derived MSCs, and further studies are needed to specify the nature of derived MSCs and if all of the derived MSCs correspond to the similar (tissue-specific) MSC type.

Finally, the use of pluripotent stem cell-derived MSCs could be limited due to allogenic rejection or teratoma formation. In particular, the clinical use of the successful generated MSCs from human iPSCs and embryonic stem cells has been hampered by the tumorigenic potential elicited by undifferentiated iPSCs and embryonic stem cell-derived MSCs, and further studies are needed to specify the nature of derived MSCs and if all of the derived MSCs correspond to the similar (tissue-specific) MSC type.

Beside the abundant origins but low frequencies of tissue-specific MSCs, the potentials to generate patient-individualized MSCs with comparable properties that bypass the immunogenicity and ethical issues in therapeutically

7. Conclusion

Beside the abundant origins but low frequencies of tissue-specific MSCs, the potentials to generate patient-individualized MSCs with comparable properties that bypass the immunogenicity and ethical issues in therapeutically
relevant numbers are central advantages of using somatic cells and iPSCs as MSC source. Concerning the proliferative and regenerative potency of generated MSC, iPSC-derived MSC may be superior to somatic cell-derived MSC because MSCs differentiated from iPSCs might be closer to fetal MSCs, since pluripotent stem cells represent the early time point in development. In contrast, the tumorigenic potential of undifferentiated iPSCs in a population of iPSC-derived MSCs is a significant safety concern for iPSC-related clinical applications. This risk might be further reduced by the use of MSCs derived from integration-free iPSCs. An alternative quite promising method to gain MSCs in vitro is the direct conversion of somatic cells, for example, easily accessible fibroblasts or blood cells. However, respective studies and standardized protocols used to prepare large-scale MSC as well as useful tests to compare their potency are limited up to now. The significant molecular and functional differences in the properties of the generated MSCs according to their different origins influence the respective therapeutic potential. Therefore, the identification of the (tissue-specific) nature of in vitro generated MSCs from pluripotent stem cells needs further investigations as well as the establishment of protocols which would allow the generation of tissue-specific MSCs. Finally, the somatic memory of iPSCs should be carefully considered before clinical translation. Up to now, there are no reports on the direct comparison of MSCs generated by different approaches, which must be investigated in future studies together with the clinical safety of different MSC sources. Concerning the patient-derived autologous MSCs generated in vitro, the respective genetic background should be a benefit for (disease) modeling studies, but the same genetic or acquired abnormalities that predisposed a patient to a particular disease will be persisted in the respective MSCs which might result in dysfunctional MSCs with reduced therapeutically activities.

Conflicts of Interest

The author states that there are no personal or institutional conflicts of interest.

Acknowledgments

The Jürgen Manchot Stiftung (Düsseldorf, Germany) supported this work.

References

[1] A. P. Chidgey, D. Layton, A. Trounson, and R. L. Boyd, “Tolerance strategies for stem-cell–based therapies,” Nature, vol. 453, no. 7193, pp. 330–337, 2008.
[2] B. Kristjansson and S. Honosawek, “Current perspectives in mesenchymal stem cell therapies for osteoarthritis,” Stem Cells International, vol. 2014, Article ID 194318, 13 pages, 2014.
[3] S. Rafii and D. Lyden, “Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration,” Nature Medicine, vol. 9, no. 6, pp. 702–712, 2003.
[4] A. Uccelli, L. Moretta, and V. Pistoia, “Mesenchymal stem cells in health and disease,” Nature Reviews Immunology, vol. 8, no. 9, pp. 726–736, 2008.
[5] I. B. Copland, “Mesenchymal stromal cells for cardiovascular disease,” Journal of Cardiovascular Disease Research, vol. 2, no. 1, pp. 3–13, 2011.
[6] K. Komatsu, O. Honmou, J. Suzuki, K. Houkin, H. Hamada, and J. D. Kocsis, “Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia,” Brain Research, vol. 1334, pp. 84–92, 2010.
[7] Z. Wen, S. Zheng, C. Zhou, J. Wang, and T. Wang, “Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction,” Journal of Cellular and Molecular Medicine, vol. 15, no. 5, pp. 1032–1043, 2011.
[8] W. R. Otto and N. A. Wright, “Mesenchymal stem cells: from experiment to clinic,” Fibrogenesis & Tissue Repair, vol. 4, no. 1, p. 20, 2011.
[9] R. R. Sharma, K. Pollock, A. Hubel, and D. McKenna, “Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices,” Transfusion, vol. 54, no. 5, pp. 1418–1437, 2014.
[10] M. Dominici, K. le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.
[11] V. B. Fernandez Vallone, M. A. Romanuik, H. Choi, V. Labovský, J. Otáegui, and N. A. Chasseing, “Mesenchymal stem cells and their use in therapy: what has been achieved?,” Differentiation, vol. 85, no. 1–2, pp. 1–10, 2013.
[12] M. Conese, A. Carbone, S. Castellani, and S. Di Gioia, “Paracrine effects and heterogeneity of marrow-derived stem/progenitor cells: relevance for the treatment of respiratory diseases,” Cells, Tissues, Organs, vol. 197, no. 6, pp. 445–473, 2013.
[13] A. De Becker and I. V. Riet, “Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy?,” World Journal of Stem Cells, vol. 8, no. 3, pp. 73–87, 2016.
[14] J. Leibacher and R. Henschler, “Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells,” Stem Cell Research & Therapy, vol. 7, no. 1, pp. 7, 2016.
[15] E. Martani and A. Facchini, “Clinical applications and biosafety of human adult mesenchymal stem cells,” Current Pharmaceutical Design, vol. 18, no. 13, pp. 1821–1845, 2012.
[16] S. Wang, X. Qu, and R. C. Zhao, “Clinical applications of mesenchymal stem cells,” Journal of Hematology & Oncology, vol. 5, no. 1, p. 19, 2012.
[17] P. Bader, Z. Kuçi, S. Bakhtiar et al., “Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM),” Bone Marrow Transplantation, vol. 53, no. 7, pp. 852–862, 2018.
[18] P. Connick and S. Chandran, “Mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in amyotrophic lateral sclerosis,” Cytotherapy, vol. 16, no. 8, pp. 1031–1032, 2014.
[19] P. Connick, M. Kolappan, C. Crawley et al., “Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a
proof-of-concept study,” The Lancet Neurology, vol. 11, no. 2, pp. 150–156, 2012.

[20] S. Fujii, Y. Miura, A. Fujishiro et al., “Graft-versus-host disease amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of naive T cell populations,” Stem Cells, vol. 36, no. 3, pp. 434–445, 2018.

[21] F. Marofi, G. Vahedi, A. Biglari, A. Esmaeilzadeh, and S. S. Athari, “Mesenchymal stromal/stem cells: a new era in the cell-based targeted gene therapy of cancer,” Frontiers in Immunology, vol. 8, article 1770, 2017.

[22] E. K. Sage, R. M. Thakrar, and S. M. Janes, “Genetically modified mesenchymal stromal cells in cancer therapy,” Cytotherapy, vol. 18, no. 11, pp. 1435–1445, 2016.

[23] Y. Yu, Y. Liu, C. Zong et al., “Mesenchymal stem cells with Sirt1 overexpression suppress breast tumor growth via chemokine-dependent natural killer cells recruitment,” Scientific Reports, vol. 6, no. 1, article 35998, 2016.

[24] M. Crisan, S. Yap, L. Casteilla et al., “A perivascular origin for mesenchymal stem cells in multiple human organs,” Cell Stem Cell, vol. 3, no. 3, pp. 301–313, 2008.

[25] D. Klein, P. Weisshardt, V. Kleff, H. Jastrov, H. G. Jakob, and S. Ergun, “Vascular wall-resident CD44+ multipotent stem cells give rise to pericytes and smooth muscle cells and contribute to new vessel maturation,” PLoS One, vol. 6, no. 5, article e20540, 2011.

[26] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999.

[27] V. Tirino, F. Paino, R. d’Aquino, V. Desiderio, A. de Rosa, and G. Papaccio, “Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives,” Stem Cell Reviews, vol. 7, no. 3, pp. 608–615, 2011.

[28] S. A. Wexler, C. Donaldson, P. Denning-Kendall, C. Rice, B. Bradley, and J. M. Hews, “Adult bone marrow is a rich source of human mesenchymal ‘stem’ cells but umbilical cord and mobilized adult blood are not,” British Journal of Haematology, vol. 121, no. 2, pp. 366–374, 2003.

[29] W. Zhao, D. G. Phinney, D. Bonnet, M. Dominici, and G. Papaccio, “Mesenchymal stem cell biodistribution, migration, and homing in vivo,” Stem Cells International, vol. 2014, Article ID 292109, 2 pages, 2014.

[30] P. J. Ho, M. L. Yen, B. C. Tang, C. T. Chen, and B. L. Yen, “$H_2O_2$ accumulation mediates differentiation capacity alteration, but not proliferative decline, in senescent human fetal mesenchymal stem cells,” Antioxidants & Redox Signaling, vol. 18, no. 15, pp. 1895–1905, 2013.

[31] C. Kyriakou, N. Rabin, A. Pizzy, A. Nathwani, and K. Yong, “Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model,” Haematologica, vol. 93, no. 10, pp. 1457–1465, 2008.

[32] Y. Liu, A. J. Goldberg, J. E. Dennis, G. A. Gronowicz, and L. T. Kuhn, “One-step derivation of mesenchymal stem cell (MSC)-like cells from human pluripotent stem cells on a fibrillar collagen coating,” PLoS One, vol. 7, no. 3, article e33225, 2012.

[33] M. Mimeault and S. K. Batra, “Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications,” Ageing Research Reviews, vol. 8, no. 2, pp. 94–112, 2009.

[34] M. Miura, Y. Miura, H. M. Padilla-Nash et al., “Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation,” Stem Cells, vol. 24, no. 4, pp. 1095–1103, 2006.

[35] W. J. C. Rombouts and R. E. Ploemacher, “Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture,” Leukemia, vol. 17, no. 1, pp. 160–170, 2003.

[36] J. Galipeau, “The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?,” Cytotherapy, vol. 15, no. 1, pp. 2–8, 2013.

[37] E. A. Kimbrel, N. A. Kouris, G. J. Yavanian et al., “Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties,” Stem Cells and Development, vol. 23, no. 14, pp. 1611–1624, 2014.

[38] A. Tyndall, “Mesenchymal stem cell treatments in rheumatology: a glass half full?,” Nature Reviews Rheumatology, vol. 10, no. 2, pp. 117–124, 2014.

[39] W. Wagner and A. D. Ho, “Mesenchymal stem cell preparations—comparing apples and oranges,” Stem Cell Reviews, vol. 3, no. 4, pp. 239–248, 2007.

[40] I. Budniatzky and L. Gepstein, “Concise review: reprogramming strategies for cardiovascular regenerative medicine: from induced pluripotent stem cells to direct reprogramming,” Stem Cells Translational Medicine, vol. 3, no. 4, pp. 448–457, 2014.

[41] D. Klein, “iPSCs-based generation of vascular cells: reprogramming approaches and applications,” Cellular and Molecular Life Sciences: CMLS, vol. 75, no. 8, pp. 1411–1433, 2018.

[42] L. Kurian, I. Sancho-Martinez, E. Nivet et al., “Conversion of human fibroblasts to angioblast-like progenitor cells,” Nature Methods, vol. 10, no. 1, pp. 77–83, 2013.

[43] C. Xu, J. Jiang, V. Sottile, J. McWhir, J. Lebkowski, and J. McWhir, “Immortalized fibroblast-like cells derived from human embryonic stem cells support undifferentiated cell growth,” Stem Cells, vol. 22, no. 6, pp. 972–980, 2004.

[44] S. Shi, S. Gronthos, S. Chen et al., “Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression,” Nature Biotechnology, vol. 20, no. 6, pp. 587–591, 2002.

[45] T. Barberi, L. M. Willis, N. D. Socci, and L. Studer, “Derivation of multipotent mesenchymal precursors from human embryonic stem cells,” PLoS Medicine, vol. 2, no. 6, article e161, 2005.

[46] Q. Lian, E. Lye, K. Suan Yeo et al., “Derivation of clinically compliant MSCs from CD105+, CD24− differentiated human ESCs,” Stem Cells, vol. 25, no. 2, pp. 425–436, 2007.

[47] C. Ellerstrom, R. Strehl, K. Moya et al., “Derivation of a xenofree human embryonic stem cell line,” Stem Cells, vol. 24, no. 10, pp. 2170–2176, 2006.

[48] C. Karlsson, K. Emanuelsson, F. Wessberg et al., “Human embryonic stem cell-derived mesenchymal progenitors—potential in regenerative medicine,” Stem Cell Research, vol. 3, no. 1, pp. 39–50, 2009.
[49] G. M. de Peppo, S. Svensson, M. Lenneras et al., "Human embryonic mesodermal progenitors highly resemble human mesenchymal stem cells and display high potential for tissue engineering applications," Tissue Engineering Part A, vol. 16, no. 7, pp. 2161–2182, 2010.

[50] Y. Jung, G. Bauer, and J. A. Nolta, "Concise review: induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products," Stem Cells, vol. 30, no. 1, pp. 42–47, 2012.

[51] T. Ma, M. Xie, T. Laurent, and S. Ding, "Progress in the reprogramming of somatic cells," Circulation Research, vol. 112, no. 3, pp. 562–574, 2013.

[52] H. Okano, M. Nakamura, K. Yoshida et al., "Steps toward safe cell therapy using induced pluripotent stem cells," Circulation Research, vol. 112, no. 3, pp. 523–533, 2013.

[53] J. Frobel, H. Hemeda, M. Lenz et al., "Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells," Stem Cell Reports, vol. 3, no. 3, pp. 414–422, 2014.

[54] C. Roux, G. Saviane, J. Pini et al., "Immunosuppressive mesenchymal stromal cells derived from human-induced pluripotent stem cells induce human regulatory T cells in vitro and in vivo," Frontiers in Immunology, vol. 8, 2018.

[55] J. Steens, M. Zulk, M. Benchellal et al., "In vitro generation of vascular wall-resident multipotent stem cells of mesenchymal nature from murine induced pluripotent stem cells," Stem Cell Reports, vol. 8, no. 4, pp. 919–932, 2017.

[56] Q. Lian, Y. Zhang, J. Zhang et al., "Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice," Circulation, vol. 121, no. 9, pp. 1113–1123, 2010.

[57] M. Giuliani, N. Oudrhiri, Z. M. Noman et al., "Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery," Blood, vol. 118, no. 12, pp. 3254–3262, 2011.

[58] J. Zhang, Y. C. Chan, J. C. Y. Ho, C. W. Stu, Q. Lian, and H. F. Tse, "Regulation of cell proliferation of human induced pluripotent stem cell-derived mesenchymal stem cells via ether-a-go-go 1 (hEAG1) potassium channel," American Journal of Physiology-Cell Physiology, vol. 303, no. 2, pp. C115–C125, 2012.

[59] D. Medici and A. Nawshad, "Type I collagen promotes epithelial-mesenchymal transition through ILK-dependent activation of NF-κB and LEF-1," Matrix Biology, vol. 29, no. 3, pp. 161–165, 2010.

[60] Y. S. Chen, R. A. Pelekanos, R. L. Ellis, R. Horne, E. J. Wolve-tang, and N. M. Fisk, "Small molecule mesenogenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells," Stem Cells Translational Medicine, vol. 1, no. 2, pp. 83–95, 2012.

[61] K. Hynes, D. Menicanin, K. Mrozik, S. Grontos, and P. M. Bartold, "Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines," Stem Cells and Development, vol. 23, no. 10, pp. 1084–1096, 2014.

[62] C. Luzzani, G. Neiman, X. Garate et al., "A therapy-grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement," Stem Cell Research & Therapy, vol. 6, no. 1, p. 6, 2015.

[63] Y. Chen, B. Stevens, J. Chang, J. Milbrandt, B. A. Barres, and J. W. Hell, "NS21: re-defined and modified supplement B27 for neuronal cultures," Journal of Neuroscience Methods, vol. 171, no. 2, pp. 239–247, 2008.

[64] A. Flemming, K. Schallmoser, D. Strunk, M. Stolk, H. D. Volk, and M. Seifert, "Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells in human platelet lysate," Journal of Clinical Immunology, vol. 31, no. 6, pp. 1143–1156, 2011.

[65] P. Ludicone, D. Fioravanti, G. Bonanno et al., "Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells," Journal of Translational Medicine, vol. 12, no. 1, p. 28, 2014.

[66] S. Kinzebach, L. Dietz, H. Kluter, H. J. Thierse, and K. Bieback, "Functional and differential proteomic analyses to identify platelet derived factors affecting ex vivo expansion of mesenchymal stromal cells," BMC Cell Biology, vol. 14, no. 1, p. 48, 2013.

[67] J. J. Auletta, E. A. Zale, J. F. Welter, and L. A. Solchaga, "Fibroblast growth factor-2 enhances expansion of human bone marrow-derived mesenchymal stromal cells without diminishing their immunosuppressive potential," Stem Cells International, vol. 2011, Article ID 235176, 10 pages, 2011.

[68] N. Fekete, M. Gadelorge, D. Fürst et al., "Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components," Cytotherapy, vol. 14, no. 5, pp. 540–554, 2012.

[69] C. D. Luzzani and S. G. Miriuka, "Pluripotent stem cells as a robust source of mesenchymal stem cells," Stem Cell Reviews, vol. 13, no. 1, pp. 68–78, 2017.

[70] D. Klein, M. Benchellal, V. Kleff, H. G. Jakob, and S. Ergun, "Hox genes are involved in vascular wall-resident multipotent stem cell differentiation into smooth muscle cells," Scientific Reports, vol. 3, no. 1, article 2178, 2013.

[71] X. Meng, R. J. Su, D. J. Baylink et al., "Rapid and efficient reprogramming of human fetal and adult blood CD34+ cells into mesenchymal stem cells with a single factor," Cell Research, vol. 23, no. 5, pp. 658–672, 2013.

[72] W. Chen, D. J. Baylink, K. H. William Lau, and X. B. Zhang, "Generation of mesenchymal stem cells by blood cell reprogramming," Current Stem Cell Research & Therapy, vol. 11, no. 2, pp. 114–121, 2016.

[73] P. L. Lai, H. Lin, S. F. Chen et al., "Efficient generation of chemically induced mesenchymal stem cells from human dermal fibroblasts," Scientific Reports, vol. 7, no. 1, article 44534, 2017.

[74] F. Gao, S. M. Chiu, D. A. L. Motan et al., "Mesenchymal stem cells and immunomodulation: current status and future prospects," Cell Death & Disease, vol. 7, no. 1, article e2062, 2016.

[75] Y. J. Jeon, J. Kim, J. H. Cho, H. M. Chung, and J. I. Chae, "Comparative analysis of human mesenchymal stem cells derived from bone marrow, placenta, and adipose tissue as sources of cell therapy," Journal of Cellular Biochemistry, vol. 117, no. 5, pp. 1112–1125, 2016.

[76] P. S. in ’t Anker, W. A. Noort, S. A. Scherjon et al., "Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential," Haematologica, vol. 88, no. 8, pp. 845–852, 2003.

[77] A. Ribeiro, P. Laranjeira, S. Mendes et al., "Mesenchymal stem cells from umbilical cord matrix, adipose tissue and
bone marrow exhibit different capabilities to suppress peripheral blood B, natural killer and T cells,” *Stem Cell Research & Therapy*, vol. 4, no. 5, p. 125, 2013.

[78] J. J. Montesinos, E. Flores-Figueroa, S. Castillo-Medina et al., “Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression,” *Cytotherapy*, vol. 11, no. 2, pp. 163–176, 2009.

[79] S. J. Prasanna, D. Gopalakrishnan, S. R. Shankar, and A. B. Vasandian, “Pro-inflammatory cytokines, IFNγ and TNFα, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially,” *PLoS One*, vol. 5, no. 2, article e9016, 2010.

[80] X. Wang, E. A. Kimbel, K. Ijichi et al., “Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis,” *Stem Cell Reports*, vol. 3, no. 1, pp. 115–130, 2014.

[81] H. Wegmeyer, A. M. Bröske, M. Leddin et al., “Mesenchymal stromal cell characteristics vary depending on their origin,” *Stem Cells and Development*, vol. 22, no. 19, pp. 2606–2618, 2013.

[82] Z.-Y. Zhang, S. H. Teoh, M. S. K. Chong et al., “Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells,” *Stem Cells*, vol. 27, no. 1, pp. 126–137, 2009.

[83] K. B. Ackema and J. Charite, “Mesenchymal stem cells from different organs are characterized by distinct topographic *Hox* codes,” *Stem Cells and Development*, vol. 17, no. 5, pp. 979–992, 2008.

[84] B. Sági, P. Maraghechi, V. S. Urbán et al., “Positional identity of murine mesenchymal stem cells resident in different organs is determined in the postsegmentation mesoderm,” *Stem Cells and Development*, vol. 21, no. 5, pp. 814–828, 2012.

[85] S. Liedtke, A. Buchheiser, J. Bosch et al., “The *HOX* code as a “biological fingerprint” to distinguish functionally distinct stem cell populations derived from cord blood,” *Stem Cell Research*, vol. 5, no. 1, pp. 40–50, 2010.

[86] Z. Hamidouche, K. Rother, J. Przybilla et al., “Bistable epigenetic states explain age-dependent decline in mesenchymal stem cell heterogeneity,” *Stem Cells*, vol. 35, no. 3, pp. 694–704, 2017.

[87] D. G. Phinney, “Functional heterogeneity of mesenchymal stem cells: implications for cell therapy,” *Journal of Cellular Biochemistry*, vol. 113, no. 9, pp. 2806–2812, 2012.

[88] M. Baddoo, K. Hill, R. Wilkinson et al., “Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection,” *Journal of Cellular Biochemistry*, vol. 89, no. 6, pp. 1235–1249, 2003.

[89] N. Tremain, J. Korkko, D. Ibberson, G. C. Kopen, C. DiGirolamo, and D. G. Phinney, “MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages,” *Stem Cells*, vol. 19, no. 5, pp. 408–418, 2001.

[90] D. Klein, A. Schmetter, R. Imsak et al., “Therapy with multipotent mesenchymal stromal cells protects lungs from radiation-induced injury and reduces the risk of lung metastasis,” *Antioxidants & Redox Signaling*, vol. 24, no. 2, pp. 53–69, 2016.

[91] D. Klein, J. Steens, A. Wiesemann et al., “Mesenchymal stem cell therapy protects lungs from radiation-induced endothelial cell loss by restoring superoxide dismutase 1 expression,” *Antioxidants & Redox Signaling*, vol. 26, no. 11, pp. 563–582, 2017.

[92] S. A. Doppler, M.-A. Deutsch, R. Lange, and M. Krane, “Direct reprogramming—the future of cardiac regeneration?,” *International Journal of Molecular Sciences*, vol. 16, no. 8, pp. 17368–17393, 2015.

[93] P. S. Hou, C. Y. Chuang, C. H. Yeh et al., “Direct conversion of human fibroblasts into neural progenitors using transcription factors enriched in human ESC-derived neural progenitors,” *Stem Cell Reports*, vol. 8, no. 1, pp. 54–68, 2017.

[94] D. Nakamori, H. Akamine, K. Takayama, F. Sakurai, and H. Mizuguchi, “Direct conversion of human fibroblasts into hepatocyte-like cells by ATF5, PROX1, FOXA2, FOXA3, and HNF4A transduction,” *Scientific Reports*, vol. 7, no. 1, article 16675, 2017.

[95] M. B. Victor, M. Richner, H. E. Olsen et al., “Striatal neurons directly converted from Huntington’s disease patient fibroblasts recapitulate age-associated disease phenotypes,” *Nature Neuroscience*, vol. 21, no. 3, pp. 341–352, 2018.

[96] W. Wagner, S. Bork, P. Horn et al., “Aging and replicative senescence have related effects on human stem and progenitor cells,” *PLoS One*, vol. 4, no. 6, article e8546, 2009.

[97] A. Stolzing, E. Jones, D. McGonagle, and A. Scutt, “Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies,” *Mechanisms of Ageing and Development*, vol. 129, no. 3, pp. 163–173, 2008.

[98] Z. Ghosh, K. D. Wilson, Y. Wu, S. Hu, T. Quertermous, and J. C. Wu, “Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells,” *PLoS One*, vol. 5, no. 2, article e8975, 2010.

[99] M. Stadtfeld, E. Apostolou, H. Akutsu et al., “Ablation of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells,” *Nature*, vol. 465, no. 7295, pp. 175–181, 2010.

[100] A. Urbach, O. Bar-Nur, G. Q. Daley, and N. Benvenisty, “Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells,” *Cell Stem Cell*, vol. 6, no. 5, pp. 407–411, 2010.

[101] S. Hu, M. T. Zhao, F. Jahanbani et al., “Effects of cellular origin on differentiation of human induced pluripotent stem cell-derived endothelial cells,” *JCI Insight*, vol. 1, no. 8, 2016.